Clinical situations associated with difficult-to-control hypertension

Journal of Hypertension

Volumn 31, Issue SUPPL. 1, 2013, Pages

  Oliveras, Anna ^a   Schmieder, Roland E ^b  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

blood pressure control; resistant hypertension; uncontrolled hypertension

Indexed keywords

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; EUROPE; HUMAN; HYPERTENSION; KIDNEY FAILURE; LIFESTYLE; MORBIDITY; OBESITY; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; RESISTANT HYPERTENSION; SALT INTAKE; SLEEP DISORDERED BREATHING; SYSTOLIC BLOOD PRESSURE; UNITED STATES;

EID: 84873652975     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32835d2af0     Document Type: Article

References (42)

1. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effect of treatment on morbidity in hypertension: results in patients with diastolic blood pressure averaging 115-129mm Hg. J Am Med Assoc 1967; 202:1038-1034.
2. Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005; 18:1422-1428.
3. Redón J, Campo C, Narciso ML, Rodicio JL, Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 1998; 31:712-718.
4. Salles GF, Cardoso CRL, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med 2008; 168:2340-2346.
5. De la Sierra A, Banegas JR, Segura J, Gorostidi M, Ruilope LM, CARDIORISC Event Investigators. Ambulatory blood pressure monitoring and development of cardiovascular events in high-risk patients included in the Spanish ABPM registry: the CARDIORISC Event study. J Hypertens 2012; 30:713-719.
6. Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 2003; 41:1341-1345.
7. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001; 19:2063-2070.
8. Muxfeldt ES, Bloch KV, Nogueira Ada R, Salles GF. True resistant hypertension: is it possible to be recognized in the office? Am J Hypertens 2005; 18 (12 Pt 1):1534-1540.
9. Oliveras A, Armario P, Hernández-del Rey R, Arroyo JA, Poch E, Larrousse M, et al. Urinary albumin excretion is associated with true resistant hypertension. J Hum Hypertens 2010; 24:27-33.
10. de la Sierra A, Banegas JR, Oliveras A, Gorostidi M, Segura J, de la Cruz JJ, et al. Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs. J Hypertens 2012; 30:1211-1216.
11. Mancia G, de Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
12. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment-a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403-1419.
13. De la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57:898-902.
14. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57:1076-1080.
15. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. J Am Med Assoc 2010; 303:2043-2050.
16. Banegas JR, López-Garc?́a E, Dallongeville J, Guallar E, Halcox JP, Borghi C, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J 2011; 32:2143-2152.
17. Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifirò G, Cricelli C, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005; 23: 2093-2100.
18. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005; 23:2101-2107.
19. Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012; 59:1124-1131.
20. Banegas JR, Segura J, Ruilope LM, Luque M, Garc?́a-Robles R, Campo C, et al. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 2004; 43:1338-1344.
21. Banegas JR, Lundelin K, de la Figuera M, de la Cruz JJ, Graciani A, Rodr?́guez-Artalejo F, Puig JG. Physician perception of blood pressure control and treatment behavior in high-risk hypertensive patients: a cross-sectional study. PLoS One 2011; 6:e24569.
22. Singer GM, Izhar M, Black HR. Goal-oriented hypertension management: translating clinical trials to practice. Hypertension 2002; 40:464-469.
23. Oliveras A, Armario P, Martell N, Ruilope LM, de la Sierra A. Urinary albumin excretion is associated with nocturnal systolic blood pressure in resistant hypertensives. Hypertension 2011; 57:556-560.
24. Midgley JP, Matthew AG, Greenwood CMT, Logan AG. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. J Am Med Assoc 1996; 275:1590-1597.
25. He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens 2002; 16:761-770.
26. Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension. Results from a randomized trial. Hypertension 2009; 54:475-481.
27. Armario P, Oliveras A, Hernández del Rey R, Ruilope LM, de la Sierra A. Grupo de Investigadores del Registro de Hipertensión Refractaria de la Sociedad Española de Hipertensión/Liga Española para la Lucha contra la Hipertensión Arterial (SEH-LELHA). Prevalence of target organ damage and metabolic abnormalities in resistant hypertension. Med Clin (Barc) 2011; 137:435-439; [Article in Spanish].
28. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011; 123:1940-1946.
29. Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 2006; 48:787-796.
30. Rahmouni K. Obesity, sympathetic overdrive, and hypertension: the leptin connection. Hypertension 2010; 55:44-45.
31. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002; 39: 982-988.
32. Gaddam KK, Nishizaka MK, Prattt-Ubunama MN, Pimenta E, Aban I, Oparil S, Calhoun DA. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168:1159-1164.
33. Ram CV. Review of resistant hypertension. Curr Hypertens Rep 2006; 8:398-402.
34. Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LKG, Amaro ACS, et al. Obstructive Sleep Apnea. The most common secondary cause of hypertension associated with resistant hypertension. Hypertension 2011; 58:811-817.
35. Lloberes P, Lozano L, Sampol G, Romero O, Jurado MJ, R?́os J, et al. Obstructive sleep apnoea and 24-h blood pressure in patients with resistant hypertension. J Sleep Res 2010; 19:597-602.
36. Gonçalves SC, Mart?́nez D, Gus M, de Abreu-Silva EO, Bertoluci C, Dutra I, et al. Obstructive sleep apnea and resistant hypertension: a case-control study. Chest 2007; 132:1858-1862.
37. Parati G, Lombardi C, Hedner J, Bonsignore MR, Grote L, Tkacova R, et al., on behalf of the EU COST ACTION B26 members. Position paper on the management of patients with obstructive sleep apnea and hypertension: Joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of the European COST (COoperation in Scientific and Technological research) ACTION B26 on Obstructive Sleep Apnea. J Hypertens 2012; 30:633-646.
38. Schmieder RE, Schrader J, Zidek W, Tebbe U, Paar WD, Bramlage P, et al. Low-grade albuminuria and cardiovascular risk. What is the evidence? Clin Res Cardiol 2007; 96:247-257.
39. Schmieder RE, Mann JFE, Schumacher H, Gao P, Mancia G, Weber MA, et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011; 22:1353-1364.
40. Rossi GP, Seccia TM, Maniero C, Pessina AC. Drug-related hypertension and resistance to antihypertensive treatment: a call for action. J Hypertens 2011; 29:2295-2309.
41. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011; 124:1046-1058.
42. De la Sierra A, Larrousse M, Oliveras A, Armario P, Hernández-del Rey R, Poch E, Roca-Cusachs A. Abnormalities of vascular function in resistant hypertension. Blood Press 2012; 21:104-109.